Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

David Einhorn Trims Apple (AAPL) Stake, Buys Calpine (CPN), Rite Aid (RAD)

Page 1 of 2

Founded in 1996 by David Einhorn with an initial capital of $900,000, Greenlight Capital has grown into one of the most famous hedge funds around, currently overseeing more than $8 billion worth of assets. After a tough 2015 that saw the fund’s positions generate a 20% loss driven mainly by the slump in the energy markets, at the end of the 2016 second quarter Greenlight Capital was up by 0.4%, after market swings wiped out most of the 3% gain it registered during the first quarter. As they look to get back to winning ways, Einhorn and his team have made some notable changes to the fund’s equity portfolio. Valued at $5.45 billion at the end of June, the fund’s equity bets were spread across a number of sectors, with an emphasis on consumer discretionary, technology and industrial sectors. Among the most prominent moves, was Greenlight’s U-turn with regard to Macy’s Inc (NYSE:M) and a 16% reduction of its top holding – Apple Inc. (NASDAQ:AAPL).

While there are many metrics that investors can assess in the investment process, hedge fund sentiment is something that is often overlooked. However, hedge funds and other institutional investors allocate significant resources while making their bets and their long-term focus makes them the perfect investors to emulate. This is supported by our research, which determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor beat the S&P 500 by around 95 basis points per month (see more details here).

David Einhorn

David Einhorn
David Einhorn
Greenlight Capital

Playing It Safely with Apple

David Einhorn has been a fan of Apple Inc. (NASDAQ:AAPL) for a long time, but the recent uncertainty regarding the company’s growth potential have prompted Greenlight Capital to cut its exposure to the stock. According to its latest 13F filing, the fund reduced its stake by 16% to 6.85 million shares worth approximately $655 million at the end of the second quarter. Apple Inc. (NASDAQ:AAPL) stock has registered some major swings so far this year, but Greenlight Capital managed to offset some of the losses incurred by the long positions by actively trading the stock, according to its recent investor letter. Investors are currently gearing up for the launch of the new iPhone 7, hoping the release will provide a boost to the stock. Recent versions of the iconic smartphone have been criticized to lack any substantial innovation, sparking concerns about Apple’s ability to gain an edge in this saturated and highly competitive market. Warren Buffett‘s Berkshire Hathaway, on the other hand, had its stake in Apple Inc. (NASDAQ:AAPL) increased by 55% to 15.2 million shares worth $1.45 billion.

Follow Apple Inc (NASDAQ:AAPL)
Trade (NASDAQ:AAPL) Now!

Bullish On Mylan NV

During the second quarter, Einhorn and his team boosted their fund’s investment in Mylan NV (NASDAQ:MYL) by 71%, amassing 4.94 million shares valued at $214 million at the end of June. Greenlight Capital initiated the position during the 2015 fourth quarter as it saw “medium-term upside from a competitor recall, an announced share repurchase, and board review of corporate governance complaints.” Greenlight also said it expects Mylan NV (NASDAQ:MYL) to earn approximately $7 per share in 2018. For the 2016 second quarter, the company posted a profit of $168.4 million or $1.16 per share when adjusted for one-time gains and costs, marginally beating analysts’ projections of $1.15 per share. Revenue rose 8% to $2.56 billion, below estimates of $2.61 billion. Mylan NV (NASDAQ:MYL) has recently completed the acquisition of Swedish drugmaker Meda for $7.2 billion in order to gain presence into a number of emerging markets like Southeast Asia, Russia and the Middle East.

Follow Mylan N.v. (NASDAQ:MYL)
Trade (NASDAQ:MYL) Now!

Turn the page to read about three other major moves reported in Greenlight’s recent 13F filing.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!